ZA201206580B - Spirocyclic compounds and thier use as therapeutic agents and diagnostic probes - Google Patents

Spirocyclic compounds and thier use as therapeutic agents and diagnostic probes

Info

Publication number
ZA201206580B
ZA201206580B ZA2012/06580A ZA201206580A ZA201206580B ZA 201206580 B ZA201206580 B ZA 201206580B ZA 2012/06580 A ZA2012/06580 A ZA 2012/06580A ZA 201206580 A ZA201206580 A ZA 201206580A ZA 201206580 B ZA201206580 B ZA 201206580B
Authority
ZA
South Africa
Prior art keywords
therapeutic agents
diagnostic probes
spirocyclic compounds
thier
thier use
Prior art date
Application number
ZA2012/06580A
Other languages
English (en)
Inventor
Vladimir Cmiljanovic
Natasa Cmiljanovic
Bern Giese
Matthias Wymann
Original Assignee
Univ Of Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Basel filed Critical Univ Of Basel
Publication of ZA201206580B publication Critical patent/ZA201206580B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
ZA2012/06580A 2010-03-15 2012-09-03 Spirocyclic compounds and thier use as therapeutic agents and diagnostic probes ZA201206580B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1004200.0A GB201004200D0 (en) 2010-03-15 2010-03-15 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
PCT/IB2011/051047 WO2011114275A1 (en) 2010-03-15 2011-03-11 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes

Publications (1)

Publication Number Publication Date
ZA201206580B true ZA201206580B (en) 2013-05-29

Family

ID=42261530

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/06580A ZA201206580B (en) 2010-03-15 2012-09-03 Spirocyclic compounds and thier use as therapeutic agents and diagnostic probes

Country Status (15)

Country Link
US (1) US20130040934A1 (enExample)
EP (1) EP2547684A1 (enExample)
JP (1) JP2013522286A (enExample)
KR (1) KR20130086520A (enExample)
CN (1) CN102939292A (enExample)
AU (1) AU2011228703A1 (enExample)
BR (1) BR112012023320A2 (enExample)
CA (1) CA2791737A1 (enExample)
GB (1) GB201004200D0 (enExample)
MX (1) MX2012010655A (enExample)
NZ (1) NZ602292A (enExample)
RU (1) RU2012143689A (enExample)
SG (1) SG184062A1 (enExample)
WO (1) WO2011114275A1 (enExample)
ZA (1) ZA201206580B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2645968T3 (es) 2011-09-27 2017-12-11 Novartis Ag 3-(pirimidin-4-il)-oxazolidin-2-onas como inhibidores de IDH mutante
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
AU2014229313B2 (en) 2013-03-14 2016-07-28 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
AR096151A1 (es) * 2013-05-01 2015-12-09 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos
CN103483345B (zh) * 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
CN104557871B (zh) * 2013-10-28 2017-05-03 上海汇伦生命科技有限公司 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途
CA2946552A1 (en) 2014-04-25 2015-10-29 Bluebird Bio, Inc. Improved methods for manufacturing adoptive cell therapies
SG10201809379UA (en) 2014-04-25 2018-11-29 Bluebird Bio Inc Mnd promoter chimeric antigen receptors
SMT202100049T1 (it) * 2014-06-06 2021-03-15 Bluebird Bio Inc Composizioni di cellule t migliorate
SG11201700492SA (en) 2014-07-24 2017-02-27 Bluebird Bio Inc Bcma chimeric antigen receptors
JP2017532364A (ja) 2014-10-31 2017-11-02 インディビオール・ユー・ケイ・リミテッド ドーパミンｄ３レセプターのアンタゴニスト化合物
WO2016094304A2 (en) 2014-12-12 2016-06-16 Bluebird Bio, Inc. Bcma chimeric antigen receptors
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
EP3231799A1 (en) * 2016-04-14 2017-10-18 Universität Basel 4-(azetidin-1-yl)pyrimidine derivatives with anti-mitotic and anti-proliferative activity
US12109234B2 (en) 2016-11-04 2024-10-08 2Seventy Bio, Inc. Anti-BCMA CAR T cell compositions
US11339181B2 (en) * 2016-12-21 2022-05-24 Japan Tobacco Inc. Crystalline forms of a Janus kinase inhibitor
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
EP3630747A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Quinazoline derivatives as modulators of mutant kras, hras or nras
BR112020008991A2 (pt) * 2017-11-06 2020-11-17 Medshine Discovery Inc. compostos de piridopirimidina que atuam como inibidores duais de mtorc 1/2
CN108191837A (zh) * 2018-01-10 2018-06-22 贵州医科大学 PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用
CN112584833A (zh) * 2018-08-01 2021-03-30 亚瑞克西斯制药公司 杂环螺化合物及其用于治疗癌症的使用方法
AU2020398215A1 (en) * 2019-12-04 2022-06-16 Chdi Foundation, Inc. ATM kinase inhibitors and compositions and methods of use thereof
TW202525813A (zh) * 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
WO2022083569A1 (en) * 2020-10-20 2022-04-28 Amgen Inc. Heterocyclic spiro compounds and methods of use
WO2025137105A1 (en) * 2023-12-22 2025-06-26 Deciphera Pharmaceuticals, Llc Dual raf and tubulin inhibitors and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002253619B2 (en) 2001-04-27 2007-05-17 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same active ingredients
EP1877388A2 (en) * 2005-02-25 2008-01-16 Kudos Pharmaceuticals Ltd Hydrazinomethyl, hydrazonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
GB0525081D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
EP2064203A1 (en) 2006-09-14 2009-06-03 AstraZeneca AB 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
EA200901065A1 (ru) * 2007-02-06 2010-02-26 Новартис Аг Ингибиторы pi 3-киназы и способы их применения
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
CN102056927B (zh) * 2008-05-13 2014-06-25 Irm责任有限公司 作为激酶抑制剂的稠合含氮杂环及其组合物
AP2775A (en) 2008-05-23 2013-09-30 Wyeth Llc Triazine compounds as P13 kinase and MTOR inhibitors

Also Published As

Publication number Publication date
US20130040934A1 (en) 2013-02-14
SG184062A1 (en) 2012-10-30
KR20130086520A (ko) 2013-08-02
AU2011228703A1 (en) 2012-09-20
BR112012023320A2 (pt) 2016-05-24
JP2013522286A (ja) 2013-06-13
RU2012143689A (ru) 2014-04-20
CN102939292A (zh) 2013-02-20
GB201004200D0 (en) 2010-04-28
EP2547684A1 (en) 2013-01-23
NZ602292A (en) 2014-08-29
CA2791737A1 (en) 2011-09-22
WO2011114275A1 (en) 2011-09-22
MX2012010655A (es) 2012-10-05

Similar Documents

Publication Publication Date Title
ZA201206580B (en) Spirocyclic compounds and thier use as therapeutic agents and diagnostic probes
LT2364302T (lt) Triazino analogai ir jų panaudojimas kaip terapinių agentų ir diagnostikos zonų
GB2499174B (en) Self-contained patient monitor
GB2479930B (en) Coupling an ultrasound probe to the skin
EP2531153A4 (en) MEDICAL DEVICE
ZA201301387B (en) Disposable skin care device
ZA201200797B (en) Bicyclic compound and use thereof for medical purposes
PL3260128T3 (pl) Zastosowanie medyczne rozpuszczalnego CD24
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
EP2564796A4 (en) MEDICAL INSTRUMENT
GB0918392D0 (en) Diagnostic and therapeutic methods
ZA201304012B (en) Novel compound and medical use thereof
GB201004924D0 (en) Medical/cosmetic device
EP2833877A4 (en) NEW TARGETING AGENTS FOR DIAGNOSTIC AND THERAPEUTIC INDICATIONS
EP2635189A4 (en) PORTABLE DEVICE FOR EX-VIVO STIMULATION OF WHOLE BLOOD
GB201011411D0 (en) Therapeutic compounds and their use
EP2623147A4 (en) MEDICAL INSTRUMENT WITH A NEEDLE INSTALLED THEREIN
GB201204014D0 (en) Diagnostic marker compounds and their use
GB201016461D0 (en) Medical instrument
SI2566579T1 (sl) Medicinska naprava za magnetoterapijo
PL2364302T3 (pl) Analogi triazyny i ich zastosowanie jako środki terapeutyczne oraz sondy diagnostyczne
PT2364302T (pt) Análogos de triazina e a sua utilização como agentes terapêuticos e sondas de diagnóstico
GB201010154D0 (en) Needle retraction medical device
AU2010900773A0 (en) Therapeutic and diagnostic agents
GB201001436D0 (en) Non-invasive monitor